Tatsumi N, Nin T, Sannomiya Y, Kageyama T, Ohyabu H, Akasaka K, Nasu K, Yonezawa T, Tominaga N, Kitani T
Department of Laboratory Medicine, Osaka City University Medical School.
Jpn J Antibiot. 1989 May;42(5):1065-76.
One hundred ninety-eight patients with severe infections associated with hematopoietic disorders were treated with imipenem/cilastatin sodium (IPM/CS), and the efficacy and safety of the drug were evaluated. The results obtained are summarized below. 1. Out of 182 patients in whom efficacies are evaluable, responses were excellent in 50 patients, good in 52, fair in 21 and poor in 59, and the efficacy rating was 56.0%. 2. The efficacy rating in 87 patients who had failed to respond to prior treatment with other antibiotics was 58.6%. 3. There were significant differences in efficacy ratings when patients were grouped according to differences the number of neutrophils after treatment, less than 100, 101 approximately 500 and over 501/mm3. 4. The eradication rate in 38 patients from whom causative organisms were isolated was 75.8%. 5. Out of 197 patients in whom the safety was evaluable, side effects were observed in 19 patients (9.6%) and abnormal laboratory test values in 15 (7.6%).
198例患有与造血系统疾病相关的严重感染患者接受了亚胺培南/西司他丁钠（IPM/CS）治疗，并对该药物的疗效和安全性进行了评估。获得的结果总结如下。1. 在182例可评估疗效的患者中，50例患者反应极佳，52例良好，21例中等，59例较差，有效率为56.0%。2. 87例先前使用其他抗生素治疗无效的患者的有效率为58.6%。3. 根据治疗后中性粒细胞数量的差异将患者分组，即低于100、101至约500以及高于501/mm³，有效率存在显著差异。4. 38例分离出病原体的患者的根除率为75.8%。5. 在197例可评估安全性的患者中，19例（9.6%）出现副作用，15例（7.6%）出现实验室检查值异常。
